

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7573494
<b>Application Number:</b>	10821930
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3681
<b>Title of Invention:</b>	Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of anglogenesis
<b>First Named Inventor/Applicant Name:</b>	Dario Neri
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Cynthia Cervoni
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	ELLIS-0002-P02-C01
<b>Receipt Date:</b>	07-MAY-2010
<b>Filing Date:</b>	12-APR-2004
<b>Time Stamp:</b>	16:27:12
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Alberts-CellsCanBe.pdf	228910 <small>94298d156c7381340360f5dea7e625ee39f8272</small>	no	2

**Warnings:**

**Information:**

2	NPL Documents	Argraves-AminoAcids.pdf	1261037 1ba169815cd415ee0b8a198db7efbc17622 7be85a0	no	8
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	Batista-TheTwoMembranes.pdf	1101179 686ced11903a08991f64217a25130b5213a05 00622	no	10
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Bauters-Accumulation.pdf	1092053 6012906dc31f7f035a31f4ce9f8140723f83c q09	no	13
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	Berndorff-ImagingofTumor.pdf	211634 31f13f8c454518af18f02c0f6c5d1a1fbcc8e e00	no	10
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Berndorff- Raidimmunotherapy.pdf	420825 498b6d9a3ca58d8f8d8f15b072ae010813c1 1f000	no	11
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Bestagno- MembraneImmunoglobulins. pdf	807633 a8b6d37d422666cd3c8d58ce66e2a19b07 1c9f	no	7
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Blythe-Benchmarking.pdf	3232443 5d8e7cd0189294ce4dc3ff9a023d272656b e08a1	no	4
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Caldas-Humanizationofanti- CD18.pdf	848826 bd397a9f18a6c36ca0cabceec5c81945ae8e c1d3	no	12
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Casset-APeptideMimetic.pdf	687314 a27eb0815dbd306d9f9aef3adea327970b0cfd 356a	no	8
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	Castellani- TheFibronectinIsoform-1.pdf	1741905 5718512757044803649056d87ab12c8271e51d896	no	8
Warnings:					
Information:					
12	NPL Documents	Chen-AdhesionMediated.pdf	5345 791745dc158b3d4d3200821ee11b541dcfd8714	no	2
Warnings:					
Information:					
13	NPL Documents	Chien-SignificantStructural.pdf	1359826 613e12778e2d746c0048f31b2931b3da3b5d8ba1	no	5
Warnings:					
Information:					
14	NPL Documents	Chirivi-Abstract14.pdf	176673 e88e6931da1efc101237d9ba283581d6dbca2db8	no	1
Warnings:					
Information:					
15	NPL Documents	Colman-EffectsofAminoAcid. pdf	366756 6795e37386d694d13c09bc53f0349e972c51ad	no	4
Warnings:					
Information:					
16	NPL Documents	Dinkelborg-MolecularImaging. pdf	948676 791afDcc76a528c966da7b2c96505e6e6077ed	no	4
Warnings:					
Information:					
17	NPL Documents	Epstein-FDARegulation.pdf	680572 5ac7dbaf7b2b18f0930a42986d768ae97928899db	no	8
Warnings:					
Information:					
18	NPL Documents	Ffrench-Constant.pdf	1185260 36487994da120c9008eefce18c8bf05c150e3da	no	14
Warnings:					
Information:					
19	NPL Documents	Freshney-CultureofAnimalCells. pdf	815861 699c3cc988d00ac228d763475743632f63da	no	7
Warnings:					
Information:					

20	NPL Documents	Garcia-Velasco-Regulation.pdf	186939 4c62b64182709c513d95eacacdb3c2c57b4e9f	no	5
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	George-RadiometalLabeling.pdf	515892 f3a5c6918be94d4c2b74f6990539ac1163097	no	6
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Giusti-SomaticDiversification.pdf	1068895 e4474767154807c244e0a81515448f050c5463	no	5
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Glukhova-ExpressionofFibronectin.pdf	1302016 8be913d8ec58aea3881bf80f31a6d804230fe	no	10
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	Goel-99mTc.pdf	391042 f25144e44955a5d3a811bf80f31a6d8042c03e	no	9
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Greenspan-DefiningEpitopes.pdf	2980023 5a5e1c1fdms2e1dc6b07b198e96df63ec234eb	no	2
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Gussow-HumanizationofMonoclonalAntibodies.pdf	805878 f5b2ee07a95c11f4d8b681060db1c54b8ee9378	no	23
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Halin-antibody-based-CancerResearch.pdf	4280345 98cc74c7321c93a2e3c547d2884a825703b055a	no	4
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Hashimoto-Uoshima-AlternativelySpliced.pdf	1322988 44bf0be38453736c28038c2c53a728f32f8d4	no	10
<b>Warnings:</b>					
<b>Information:</b>					

29	NPL Documents	Holm-FunctionalMapping.pdf	1098744 3a0bba943d5c1234dc79c546a1419126d2476c	no	10
Warnings:					
Information:					
30	NPL Documents	Isemura-IsolationandCharacterization.pdf	359930 2e7575f56aa32a6710690943d3ba671646ba9	no	4
Warnings:					
Information:					
31	NPL Documents	Kaspar-FibronectinAsTarget.pdf	355026 891d49c1e4f78484eb6a259811fa324d61c4b4	no	9
Warnings:					
Information:					
32	NPL Documents	Katugampola.pdf	178176 4c055d76d741c054de6cc1c255b476c82a437e	no	6
Warnings:					
Information:					
33	NPL Documents	Kern-InteractionofTypeIV.pdf	907854 a6694116f9baac33de27f6abc1f77565c31d	no	9
Warnings:					
Information:					
34	NPL Documents	Kim.pdf	1734966 6d9c00e196db3cd95a296de1239f825aacc482d	no	10
Warnings:					
Information:					
35	NPL Documents	Kogan-ASingleAminoAcid.pdf	14588632 416518402272a701367ed7b9976c486c9f878c80	no	9
Warnings:					
Information:					
36	NPL Documents	Korver-Measurement.pdf	569965 6c6d66886c9d1a646f420518b77c19a872c446a	no	6
Warnings:					
Information:					
37	NPL Documents	LI-MammalianCell.pdf	818412 eae97947d0cab2baac7c3f6cfa1290c38f5c115f	no	6
Warnings:					
Information:					

38	NPL Documents	Liu-TreatmentofBCellLymphoma.pdf	1241977 81ed50866d4748ba6d5c441ec7aa55ec8f6dc6a	no	10
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	MacCallum-AntibodyAntigen.pdf	1367106 58ce7d4018a418aa1257816e65726e77e0f354	no	14
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	Magnusson-Fibronectin.pdf	793473 267a48e4c5ae0722-4bc8d5a17775b1799fb18f1	no	8
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	Mariuzza-TheStructuralBasis.pdf	1467825 e7a62236a86ca188c7bd1d5ad79e34515ae27a5	no	22
<b>Warnings:</b>					
<b>Information:</b>					
42	NPL Documents	Marty-Production.pdf	1119777 c1beef7bd119c11a11552b1de6d114a18b4951a	no	9
<b>Warnings:</b>					
<b>Information:</b>					
43	NPL Documents	Matsuura-AnAlphaNAcetyl.pdf	507550 779de6b298d6c1ce1005b0b8c578bdf1dc01d	no	5
<b>Warnings:</b>					
<b>Information:</b>					
44	NPL Documents	Matsuura-OncofetalDomain.pdf	545037 c1bfae8c252920c7b9dca0b074158f495f12d	no	5
<b>Warnings:</b>					
<b>Information:</b>					
45	NPL Documents	Menrad-ExpertOpinion1.pdf	1382226 c1d9d7654fa6c7b6244c8b2188154a06c582b	no	10
<b>Warnings:</b>					
<b>Information:</b>					
46	NPL Documents	Morikawa-RADIOimmunoassay.pdf	413893 2a0f8006dc578ba7c6c947d6a2c261038f44d	no	8
<b>Warnings:</b>					
<b>Information:</b>					

47	NPL Documents	Ngo-ComputationalComplexity.pdf	4588213 173543130927838246204e75cd651475b87	no	38
<b>Warnings:</b>					
<b>Information:</b>					
48	NPL Documents	Nozawa-HMMC-1.pdf	735334 f30d46bce9f9e8188765d88ceefbcb561ba19	no	8
<b>Warnings:</b>					
<b>Information:</b>					
49	NPL Documents	Orlova-ComparativeBiodistribution.pdf	887432 5d8ba1ee7-4651705e88bd6-33904403e9f7b	no	12
<b>Warnings:</b>					
<b>Information:</b>					
50	NPL Documents	Pascalis-Grafting.pdf	995707 e558e7b8e65245ec2e2f7296b8519104808e6e	no	10
<b>Warnings:</b>					
<b>Information:</b>					
51	NPL Documents	Pasqualini-AlphaVIntegrins.pdf	1221501 485631e618d927eb1d8e1854bbed581806de	no	6
<b>Warnings:</b>					
<b>Information:</b>					
52	NPL Documents	Poon-LaserInducedAbstract.pdf	90930 5d7e6dc3c28c80904261cbe9619004573a911fe	no	2
<b>Warnings:</b>					
<b>Information:</b>					
53	NPL Documents	Rudikoff-SingleAminoAcid.pdf	942238 8d888e501d112101c26872e6c2b79abdc5baff	no	5
<b>Warnings:</b>					
<b>Information:</b>					
54	NPL Documents	Schier-IsolationofPicomolarAffinity.pdf	1637706 8d4f13d88f6c24d875d8e618cd97ab7e173a	no	17
<b>Warnings:</b>					
<b>Information:</b>					
55	NPL Documents	Swiss-Prot-A2KBB9.pdf	37296 01c4d8ca77be000f8b49f3bf6aa38799276123d	no	1
<b>Warnings:</b>					
<b>Information:</b>					

56	NPL Documents	Swiss-Prot-A2KBC0.pdf	50456	no	1
			355aaf935da217825548b08454056ba52bf5c4		
Warnings:					
Information:					
57	NPL Documents	Swiss-Prot-A2KBC1.pdf	51579	no	1
			346cd984e471b4b4b67725a6c5d5d3a7c7cdd791378		
Warnings:					
Information:					
58	NPL Documents	Swiss-Prot-A2KBC2.pdf	51665	no	1
			1f5452a8f753d75b5-9a48124f8be9d49a5e7e48		
Warnings:					
Information:					
59	NPL Documents	Swiss-Prot-A2KBC3.pdf	50647	no	1
			e971e407138e4d8bb05b05e4345262aeabaf		
Warnings:					
Information:					
60	NPL Documents	Tait-DevelandCharac.pdf	909524	no	9
			718a4896a0121413997191e129c7108cfa7903		
Warnings:					
Information:					
Total Files Size (in bytes):			71727543		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

#### **New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

#### **National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

#### **New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.